

**Disclosure Purpose:** 22-01300

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Recombinant Plant-Based, Adjuvanted COVID-19 Vaccine
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization   |            |   |
|---|------------|---|
| Entity  | Type       | Interest Held By  |
| <a href="#">medicago</a>  | Employment | Self  |
| <i>Title:</i> Vice President Regulatory Affairs<br><i>Additional Information:</i> |            | <i>Position Description:</i> Head of Regulatory Affairs |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By             |
|---|------------|------------------------------|
| Medicago  | Employment | Self                         |
| <i>Title:</i><br><i>Additional Information:</i> |            | <i>Position Description:</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By             |
|---|------------|------------------------------|
| GlaxoSmithKline   | Employment | Self                         |
| <i>Title:</i> Chief Global Health Officer<br><i>Additional Information:</i> |            | <i>Position Description:</i> |
| GlaxoSmithKline   | Stock      | Self                         |
| <i>Additional Information:</i>  |            |                              |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization   |              |   |
|---|--------------|---|
| Entity  | Type         | Interest Held By  |
| GlaxoSmithKline   | Employment   | Self  |
| <i>Title:</i> Product Safety Lead - Adjuvants<br><i>Additional Information:</i>   |              | <i>Position Description:</i> Safety Lead for Adjuvants at GSK |
| GlaxoSmithKline   | Stock Option | Self  |
| <i>Additional Information:</i> I am employee of the GSK group of companies and holds restricted shares in the GSK group of companies. |              |   |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a plant-Based Virus-Like Particle Vaccine for COVID-19 adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization   |            |                              |
|---|------------|------------------------------|
| Entity  | Type       | Interest Held By             |
| <a href="#">Medicago Inc.</a>   | Employment | Self                         |
| <i>Title:</i> Senior Director, Scientific & Medical Affairs<br><i>Additional Information:</i> hourly rate |            | <i>Position Description:</i> |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.





**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization   |            |                              |
|---|------------|------------------------------|
| Entity  | Type       | Interest Held By             |
| <a href="#">Medicago R&amp;D</a>  | Employment | Self                         |
| <i>Title:</i> EVP Innovation, Development and Medical Affairs<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity                                   | Type       | Interest Held By             |
|--|------------|------------------------------|
| Medicago Inc                             | Employment | Self                         |
| <i>Title:</i><br>Additional Information: |            | <i>Position Description:</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS0
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity   | Type  | Interest Held By                             |
|--|-------|--|
| <a href="#">Medicago Inc.</a>                            | Other | Self   |
| <i>Category:</i> Other<br><i>Additional Information:</i> |       | <i>Description:</i> Clinical Trials Services |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization  |            |   |
|--|------------|---|
| Entity   | Type       | Interest Held By                          |
| Medicago   | Employment | Self                                      |
| <i>Title:</i> Chef Developpement de Produits<br><i>Additional Information:</i> |            | <i>Position Description:</i> Project lead |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By  |
|---|------------|---|
| <a href="#">Medicago Inc.</a>                     | Employment | Self  |
| <i>Title:</i> Sr. Director, Clinical Research     |            | <i>Position Description:</i> Head of the Clinical Studies department, including clinical operations and biometrics. |
| <i>Additional Information:</i> Full time employee |            |   |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By   |
|--|------------|--|
| <a href="#">Medicago, Inc.</a>   | Employment | Self   |
| <i>Title:</i> Clinical Principal Biostatistician<br><i>Additional Information:</i> |            | <i>Position Description:</i> biostatistician for clinical trials in humans |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

Summary of Interests

| Company or Organization   |                  |   |
|---|------------------|---|
| Entity  | Type             | Interest Held By  |
| Medicago  | Grant / Contract | Self  |
| <i>Recipient Name:</i> University Hospital NHS Foundation Trust<br><i>Grant / Contract Description:</i> Grant paid to institution to carry out research<br><i>Additional Information:</i> |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| MSD   | Grant / Contract | Self  |
| <i>Recipient Name:</i> Christine Jones<br><i>Grant / Contract Description:</i> Advisory Board<br><i>Additional Information:</i>   |                  | <i>Recipient Type:</i> Individual<br><i>Grant / Contract Purpose:</i> Research  |
| Pfizer  | Grant / Contract | Self  |
| <i>Recipient Name:</i> Christine Jones<br><i>Grant / Contract Description:</i> Consultant<br><i>Additional Information:</i>   |                  | <i>Recipient Type:</i> Individual<br><i>Grant / Contract Purpose:</i> Research  |
| Pfizer Inc.   | Grant / Contract | Self  |
| <i>Recipient Name:</i> University Hospital NHS Foundation Trust<br><i>Grant / Contract Description:</i> Research grant<br><i>Additional Information:</i>                                  |                  | <i>Recipient Type:</i> Institution<br><i>Grant / Contract Purpose:</i> Research |
| SANOFI PASTEUR INC.   | Grant / Contract | Self  |
| <i>Recipient Name:</i> Christine Jones<br><i>Grant / Contract Description:</i> Advisory Board<br><i>Additional Information:</i>   |                  | <i>Recipient Type:</i> Individual<br><i>Grant / Contract Purpose:</i> Research  |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity                                 | Type       | Interest Held By  |
|--|------------|---|
| <a href="#">medicago, Inc</a>          | Employment | Self  |
| <i>Title:</i> Chief Scientific Officer |            | <i>Position Description:</i> Chief Scientific Officer is responsible for quality assurance, quality control, PV, clinical operation and regulatory affairs. |
| <i>Additional Information:</i>         |            |   |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization                                  |            |   |
|--|------------|---|
| Entity   | Type       | Interest Held By                          |
| GSK  | Employment | Self                                      |
| <i>Title:</i> Director<br><i>Additional Information:</i> |            | <i>Position Description:</i> Project Lead |
| GSK  | Stock      | Self                                      |
| <i>Additional Information:</i>                           |            |   |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By   |
|---|------------|--|
| Medicago Inc.   | Employment | Self   |
| <i>Title:</i> Project Manager<br><i>Additional Information:</i> |            | <i>Position Description:</i> Senior Project Management in PMO department. Manage R&D projects. |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization   |            |                              |
|---|------------|------------------------------|
| Entity  | Type       | Interest Held By             |
| Medicago  | Employment | Self                         |
| <i>Title:</i> Manager - Process Development<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

## Summary of Interests

| Company or Organization                                     |            |   |
|---|------------|---|
| Entity  | Type       | Interest Held By  |
| <a href="#">Medicago Inc.</a>                               | Employment | Self  |
| <i>Title:</i> Medical Director                              |            | <i>Position Description:</i> Medical oversight of the clinical development of pharmaceutical products (vaccines). |
| <i>Additional Information:</i> permanent full-time employee |            |   |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

| Company or Organization   |                            |  |
|---|----------------------------|--|
| Entity  | Type                       | Interest Held By   |
| <a href="#">INOVIO Pharmaceuticals</a>  | Data And Safety Monitoring | Self   |
| <i>Category:</i> Data And Safety Monitoring<br><i>Additional Information:</i>                   |                            | <i>Description:</i> DSMB for their SARS-CoV-2 vaccine                                    |
| <a href="#">kentucky bioproducts</a>  | Data And Safety Monitoring | Self   |
| <i>Category:</i> Data And Safety Monitoring<br><i>Additional Information:</i>                   |                            | <i>Description:</i> DSMB for their SARS-CoV-2 vaccine                                    |
| <a href="#">Medicago</a>  | Consultant                 | Self   |
| <i>Category:</i> Consultant<br><i>Additional Information:</i> USD300/hr, for about \$10-25K/yr. |                            | <i>Description:</i> Statistical consultant for influenza and SARS-CoV-2 vaccine studies. |
| <a href="#">Pfizer Inc.</a>   | Data And Safety Monitoring | Self   |
| <i>Category:</i> Data And Safety Monitoring<br><i>Additional Information:</i>                   |                            | <i>Description:</i> On DSMBs for their RSV vaccine and Paxlovid studies                  |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization  |            |   |
|--|------------|---|
| Entity   | Type       | Interest Held By  |
| <a href="#">medicago</a>   | Employment | Self  |
| <i>Title:</i> Executive Vice President, Corporate Planning<br><i>Additional Information:</i> |            | <i>Position Description:</i> Corporate Planning, Strategy |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

## Summary of Interests

| Company or Organization  |            |                              |
|--|------------|------------------------------|
| Entity   | Type       | Interest Held By             |
| <a href="#">Medicago Inc.</a>  | Employment | Self                         |
| <i>Title:</i> Sr Biometrics Programmer<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By             |
|--|------------|------------------------------|
| Medicago Inc.  | Employment | Self                         |
| <i>Title:</i> Manager - Clinical Studies<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By             |
|---|------------|------------------------------|
| <a href="#">Medicago Inc.</a>   | Employment | Self                         |
| <i>Title:</i> Manager Clinical Immunology<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

## Summary of Interests

| Company or Organization   | Type       | Interest Held By                                |
|---|------------|---|
| <b>iTrials SA</b><br><i>Additional Information:</i> scientific site management organization | Stock      | Self  |
| <b>Janssen Biotech</b><br><i>Category:</i> Consultant<br><i>Additional Information:</i>     | Consultant | Self<br><i>Description:</i> consultation on RSV |
| <b>Merck</b><br><i>Category:</i> Consultant<br><i>Additional Information:</i>               | Consultant | Self<br><i>Description:</i> consultation on RSV |
| <b>Novavax, INC</b><br><i>Category:</i> Consultant<br><i>Additional Information:</i>        | Consultant | Self<br><i>Description:</i> consultation on RSV |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

## Summary of Interests

### Company or Organization

| Entity   | Type  | Interest Held By                    |
|--|-------|-------------------------------------|
| <a href="#">Medicago</a>   | Other | Self                                |
| <b>Category:</b> Other<br><b>Additional Information:</b> SARS COV-2 vaccine against COVID-19. Principal Investigator. I have signed a FDA Form 1572 or an Investigator Agreement. I receive funds.   |       | <b>Description:</b> Clinical Trial  |
| <a href="#">Merck</a>  | Other | Self                                |
| <b>Category:</b> Other<br><b>Additional Information:</b> Anti-RSV Antibody in Newborns. Sub-Investigator. I have signed a FDA Form 1572 or an Investigator Agreement. I have received funds.   |       | <b>Description:</b> Clinical Trial  |
| <a href="#">Pfizer</a>   | Other | Self                                |
| <b>Category:</b> Other<br><b>Additional Information:</b> 1. Anti-RSV vaccine in pregnant women. Principal Investigator (2021-?) 2. Pediatric Antireflux treatment. Principal Investigator. (2019-?) 3. SARS COV-2 RNA vaccine against COVID19. Sub-Investigator. (2021-?) - In every study I have signed a FDA Form 1572 or an Investigator Agreement. - In every study I have received funds and compensation to attend to an investigator meeting. |       | <b>Description:</b> Clinical Trials |

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By   |
|---|------------|--|
| GlaxoSmithKline   | Employment | Self   |
| <i>Title:</i> Clinical and Epi Program Lead<br><i>Additional Information:</i> |            | <i>Position Description:</i> oversight of clinical and epidemiological programs at GSK |
| GlaxoSmithKline   | Stock      | Self   |
| <i>Additional Information:</i>  |            |  |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By  |
|---|------------|---|
| <a href="#">Medicago Inc.</a>                                   | Employment | Self  |
| <i>Title:</i> Manager   |            | <i>Position Description:</i> Management of R&D collaborations of the company and academic/industrial partners |
| <i>Additional Information:</i> Full-time and permanent employee |            |   |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- 3. **Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity  | Type       | Interest Held By             |
|---|------------|------------------------------|
| Medicago Inc  | Employment | Self                         |
| <i>Title:</i> AVP Product Development<br><i>Additional Information:</i> |            | <i>Position Description:</i> |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 22-01300

### Summary of Interests

I do not have any interests to disclose at this time.

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 22-01300

**Summary of Interests**

I do not have any interests to disclose at this time.

**Additional Questions:**

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- 2. **What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-like Particle for COVID-19 Adjuvanted with AS03
- 3. **Are you the corresponding author?**  
No.

**Certification**

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-01300

## Summary of Interests

### Company or Organization

| Entity  | Type       | Interest Held By  |
|---|------------|---|
| <a href="#">Medicago R &amp; D Inc</a>                          | Employment | Self  |
| <i>Title:</i> medical officer<br><i>Additional Information:</i> |            | <i>Position Description:</i> medical officer  |
| <a href="#">Novartis</a>  | Consultant | Self  |
| <i>Category:</i> Consultant<br><i>Additional Information:</i>   |            | <i>Description:</i> Serve on expert panel to review infectious diseases risks for MS patients taking DMTs |

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
- Are you the corresponding author?**  
Yes.
  - Please list the other authors' names here.**  
Karen Joyce Hager, Gonzalo Pérez Marc, Philippe Gobeil, Ricardo Sobhie Diaz, Gretchen Heizer, Conrado Llapur, Alexander I. Makarkov, Eduardo Vasconcellos, Stephane Pillet, Fernando Riera, Kapil Bhutada, Priscila Geller Wolff, Garry Wallace, Hessam Aazami, Christine E. Jones, Fernando P. Polack, Judith Atkins, Iohann Boulay, Jiwanjeet Dhaliwall, Nathalie Charland, Manon Couture, Julia Jiang-Wright, Nathalie Landry, Sophie Lapointe, Aurélien Lorin, Asif Mahmood, Lawrence H. Moulton, Emmy Pahmer, Julie Parent, Pooja Saxena, Annie Séguin, Luan Tran, Thomas Breuer, Maria Angeles Ceregido, Marguerite Koutsoukos, François Roman, Junya Namba, Marc-André D'Aoust, Sonia Trepanier, Yosuke Kimura, Luciana Ferrara

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-01300

Summary of Interests

**Company or Organization**

| Entity   | Type       | Interest Held By  |
|--|------------|---|
| GlaxoSmithKline  | Consultant | Self  |
| <i>Category:</i> Consultant  |            | <i>Description:</i> I worked as a Principal Investigator of the clinical trial sponsored by Medicago and GSK (adjuvant) |
| <i>Additional Information:</i>   |            |   |
| The Medicines Company  | Consultant | Self  |
| <i>Category:</i> Consultant  |            | <i>Description:</i> I worked in the cinalical trial sponsored by Medicago   |
| <i>Additional Information:</i> I was principal investigator in the Clinical Trial of a Covid vaccine sponsored by Medicago |            |   |

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Efficacy and safety of a plant-based virus-like particle vaccine for Covid-19 Adjuvanted with AS03
- Are you the corresponding author?**  
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.